GALMED PHARMACEUTICALS LTD (GLMD)

IL0011313900 - Common Stock

3.05  -0.02 (-0.65%)

GALMED PHARMACEUTICALS LTD

NASDAQ:GLMD (12/20/2024, 8:14:55 PM)

3.05

-0.02 (-0.65%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%-878.46%
Sales Q2Q%N/A
CRS4.16
6 Month-19%
Overview
Earnings (Last)11-20 2024-11-20
Earnings (Next)N/A N/A
Ins Owners1.29%
Inst Owners2.32%
Market Cap4.61M
Shares1.51M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts82.86
Short Float %1.53%
Short Ratio0.26
IPO03-13 2014-03-13
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

GLMD Daily chart

Company Profile

Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).

Company Info

GALMED PHARMACEUTICALS LTD

16 Tiomkin Street

TEL AVIV-YAFO 6578317

P: 97236938448

CEO: Allen Baharaff

Employees: 6

Website: https://www.galmedpharma.com

GLMD News

News Image3 months ago - FinancialNewsMediaHow Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:MRK),(NYSE:PFE),(NASDAQ:GLMD) EQNX::TICKER_END

News Image3 months ago - FN Media Group LLCHow Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
News Image3 months ago - Galmed Pharmaceuticals Ltd.Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases

/PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for fibroinflammatory...

News Image6 months ago - InvestorPlaceGLMD Stock Earnings: Galmed Pharmaceuticals Reported Results for Q1 2024

Galmed Pharmaceuticals just reported results for the first quarter of 2024.

GLMD Twits

Here you can normally see the latest stock twits on GLMD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example